ROBERT YOLKEN, M.D.
Radiology at Wolfe St, Baltimore, MD

5505955, Apr 9, 1996

Jan 23, 1995

8/378865

Jerry A. Peterson - Lafayette CA
Robert H. Yolken - Baltimore MD
David S. Newburg - Newtonville MA

Senomed, Inc. - Walnut Creek CA
Cancer Research Fund of Contra Costa - Walnut Creek CA
The Johns Hopkins Univ. School of Medicine - Baltimore MD

A61K 4500, A61K 968

424439

An anti-diarrheic product comprises a foodstuff and an anti-rotaviral agent such as human defatted fat globule membranes, the human milk macromolecular fraction, the milk mucin complex, the 46 Kd apparent MW glycoprotein, a polypeptide having the rotavirus-binding specificity of the 46 Kd apparent MW HMFG glycoprotein, mixtures thereof, or mixtures thereof, and optionally skim milk, curd, and/or whey. They product of the invention is provided also as an anti-diarrheal kit, with instructions for its use. The product of the invention has therapeutic and prophylactic application for inhibiting the onset of, or countering, rotavirus infection and/or diarrhea, in a subject, such as for example, infants and children (infantile gasteroenteritis), travellers, and immunodeficient persons, including HIV positive and transplant patients.

5667797, Sep 16, 1997

Apr 1, 1996

8/626057

Jerry A. Peterson - Lafayette CA
David S. Newburg - Newtonville MA
Robert H. Yolken - Baltimore MD

Cancer Research Fund of Contra Costa - Walnut Creek CA
Senomed, Inc. - Walnut Creek CA
The Johns Hopkins University School of Medicine - Baltimore MD

A61K 4500

424439

An anti-diarrheic product comprises a foodstuff and an anti-rotaviral agent such as human defatted fat globule membranes, the human milk macromolecular fraction, skim milk, curd, whey, the milk mucin complex, the 46 Kd app. MW glycoprotein, a polypeptide having an amino acid sequence having the rotavirus binding specificity of the 46 Kd app. MW HMFG glycoprotein or mixtures thereof. An anti-diarrheal kit comprises the anti-rotaviral agent of this invention and instructions for its use, and optionally a foodstuff. A method for inhibiting or countering rotavirus infection in mammalian cells comprises contacting the cells with an anti-rotaviral amount of the agent of this invention. A therapeutic method for inhibiting the onset of or countering rotavirus infection comprises administering to a subject afflicted with or at risk for rotavirus infections such as those occuring, for example, in infants and children (infantile gasteroenteritis) and immunodeficient persons or those who have received a transplant, an anti-rotaviral effective amount of the agent of this invention.

8431611, Apr 30, 2013

Oct 19, 2007

12/445499

Lorraine V. Brando - Baltimore MD, US
Gary H. Posner - Baltimore MD, US
John G. D'Angelo - Lindenhurst NY, US
Robert H. Yolken - Baltimore MD, US
Christopher P. Hencken - Baltimore MD, US
Lauren Woodard - Baltimore MD, US

Johns Hopkins University - Baltimore MD

A01N 43/02, A61K 31/335

514450, 514183, 514449

This disclosure provides improved derivatives of artemisinin; pharmaceutical compositions containing these compounds; methods for preparing these compounds and compositions; methods of using these compounds and compositions for preventing, controlling or treating infectious diseases including but not limited to parasitic infectious diseases such as infection, trypanosome parasite infection, plasmodia parasite infection, and cryptosporidium parasite infection; methods for preventing, controlling or treating toxoplasma infection; and methods for treating psychiatric disorders associated with toxoplasma infection including but not limited to schizophrenia using the disclosed compounds and compositions alone or in combination with one or more antipsychotic drugs.

5192551, Mar 9, 1993

May 2, 1989

7/346450

Rodney E. Willoughby - Baltimore MD
Robert H. Yolken - Baltimore MD

Johns Hopkins University - Baltimore MD

A61K 916, A61K 3174

424489

The binding of neutral glycolipid GA1 (asialo-GM1) to a broad spectrum of enteric viruses is taught. The glycolipid can be used to pass through the gastrointestinal tract of adults and children to adsorb viral particles and remove them from the body. The glycolipid may be used alone or bound to a non-absorbable resin or matrix.